About Oscine Therapeutics
Oscine Therapeutics is a company based in New York (United States) founded in 2017 was acquired by Sana Biotechnology in November 2020. Oscine Therapeutics offers products and services including Engineered Cell Therapies and Drug Candidates. Oscine Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Sana Biotechnology
(Nov 02, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oscine Therapeutics
Oscine Therapeutics offers a comprehensive portfolio of products and services, including Engineered Cell Therapies and Drug Candidates.
Repairs genes in cells to treat diseases like cancer
Advances treatments for diabetes and autoimmune disorders
Funding Insights of Oscine Therapeutics
Detailed funding history for Oscine Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Oscine Therapeutics
Oscine Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sana Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Genetically engineered cell therapies are developed for multiple disorders.
|
Locked | Locked | Locked |
Investor details for Oscine Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oscine Therapeutics
Investment portfolio details for Oscine Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oscine Therapeutics
Detailed financials for Oscine Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oscine Therapeutics Comparisons
Peer comparison for Oscine Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oscine Therapeutics
Oscine Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapies for psychosis and cognitive impairment are developed.
|
Detailed competitors of Oscine Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oscine Therapeutics
Complete news archive for Oscine Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oscine Therapeutics
Oscine Therapeutics was founded in 2017.
Oscine Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Christina Trojel Hansen is the current CEO of Oscine Therapeutics.
Oscine Therapeutics was founded in 2017 in New York, United States, within the biotechnology sector. Stem cell-based therapeutics are developed by the company to address neurological diseases. A platform has been created to produce biopotential astrocyte-oligodendrocyte glial progenitor cells for degenerative conditions. The pipeline encompasses treatments for Pelizaeus-Merzbacher disease and secondary progressive multiple sclerosis, both in IND-toxicology stages, alongside preclinical efforts for Huntingtons disease.
Oscine Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Oscine Therapeutics offers Engineered Cell Therapies and Drug Candidates.
Oscine Therapeutics has 1 investor. Key investors include Sana Biotechnology.